Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase
Inclusion Criteria:
-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Buenos Aires, Buenos Aires C1114AAN, Argentina
Caba, Buenos Aires C1221ADC, Argentina
Concord NSW, New South Wales 2139, Australia
Tamil Nadu, Chennai 600035, India
Niaosong Township, Taiwan 83301, Taiwan
Muang, 40002, Thailand